Connect with us
Teva's first-half performance in Spain exceeds annual forecasts, with 2024 growth projected at 7.5%. The company has invested over €70 million in Spain since 2008, with...
In 2021, Teva's Spanish subsidiary had a turnover of around 412 million euros in a global context of slowing turnover, which in 2022 fell by 6%....
Teva initially got the chance to launch its drug called fremanezumab before Aimovig, but the opportunity slipped away when there was a delay in its FDA...